Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

744

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

March 30, 2026

Conditions
CarcinomaNon-Small-Cell Lung CancerAdenocarcinoma
Interventions
DRUG

Elemene plus first or third generation EGFR-TKIs

"Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label."

DRUG

First or third generation EGFR-TKIs

refer to the drug label.

Trial Locations (7)

Unknown

RECRUITING

Affiliated Hospital of Nantong University, Nantong

RECRUITING

Panjin Central Hospital, Panjin

RECRUITING

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai

RECRUITING

Sichuan Academy of Medical Sciences· Sichuan Province People's Hospital, Chengdu

RECRUITING

Hangzhou Cancer Hospital, Hangzhou

RECRUITING

Peking University Cancer Hospital, Beijing

048100

RECRUITING

The Second People's Hospital of Yangcheng County, Jincheng

All Listed Sponsors
collaborator

LinkDoc Technology (Beijing) Co. Ltd.

INDUSTRY

lead

Tian Xie

OTHER

NCT04401059 - Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study | Biotech Hunter | Biotech Hunter